Publication: Cost-effectiveness of artesunate for the treatment of severe malaria
Issued Date
2009-03-01
Resource Type
ISSN
13653156
13602276
13602276
Other identifier(s)
2-s2.0-60349111924
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Tropical Medicine and International Health. Vol.14, No.3 (2009), 332-337
Suggested Citation
Y. Lubell, S. Yeung, A. M. Dondorp, N. P. Day, F. Nosten, E. Tjitra, Md Abul Faiz, E. Bin Yunus, N. M. Anstey, S. K. Mishra, S. Mohanty, N. J. White, A. J. Mills Cost-effectiveness of artesunate for the treatment of severe malaria. Tropical Medicine and International Health. Vol.14, No.3 (2009), 332-337. doi:10.1111/j.1365-3156.2009.02227.x Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/27735
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Cost-effectiveness of artesunate for the treatment of severe malaria
Other Contributor(s)
London School of Hygiene & Tropical Medicine
Mahidol University
Shoklo Malaria Research Unit
Badan Penelitian Dan Pengembangan Kesehatan, Kementerian Kesehatan Republik Indonesia
Dhaka Medical College
Chittagong Medical College
Ispat General Hospital
London Schol of Hygiene and Tropical Medicine
Mahidol University
Shoklo Malaria Research Unit
Badan Penelitian Dan Pengembangan Kesehatan, Kementerian Kesehatan Republik Indonesia
Dhaka Medical College
Chittagong Medical College
Ispat General Hospital
London Schol of Hygiene and Tropical Medicine
Abstract
Objective: To explore the cost-effectiveness of artesunate against quinine based principally on the findings of a large multi-centre trial carried out in Southeast Asia. Methods: Trial data were used to compare mortality of patients with severe malaria, treated with either artesunate or quinine. This was combined with retrospectively collected cost data to estimate the incremental cost per death averted with the use of artesunate instead of quinine. Results: The incremental cost per death averted using artesunate was approximately 140 USD. Artesunate maintained this high level of cost-effectiveness also when allowing for the uncertainty surrounding the cost and effectiveness assessments. Conclusion: This analysis confirms the vast superiority of artesunate for treatment of severe malaria from an economic as well as a clinical perspective. © 2009 Blackwell Publishing Ltd.